05 April 2007

Steroid vs. multiple myeloma

Preliminary results from a study of patients with multiple myeloma found that a low dose of dexamethasone, in combination with lenalidomide, improved survival.

Preliminary results from a large US study of patients with newly diagnosed multiple myeloma found that a low dose of the steroid dexamethasone (brand named Decadron), in combination with lenalidomide (brand name Revlimid), improved survival when compared to a treatment regimen with lenalidomide and a higher, standard dose of dexamethasone.

Researchers reported Wednesday that patients in the study who received low-dose dexamethasone and lenalidomide had a one-year survival of 96 percent, compared to 86 percent for patients treated with the standard-dose of dexamethasone and lenalidomide. Also, there were fewer side effects associated with the low-dose dexamethasone and lenalidomide, according to the US National Cancer Institute.

Lenalidomide, a derivative of thalidomide, was approved by the US Food and Drug Administration in 2006 to be used in tandem with dexamethasone for the treatment of multiple myeloma in patients who had received at least one prior therapy for their disease. Dexamethasone is a steroid that acts as an anti-inflammatory and as an immunosuppressant.

Multiple myeloma is a cancer of plasma cells that are found in blood and bone marrow.

Results of the new study, sponsored by the US National Cancer Institute, will be presented in June at the American Society of Clinical Oncology annual meeting in Chicago. But the researchers released the findings early because they were so promising. – (HealthDayNews)

Read more:
A-Z of Multiple myeloma
Thalidomide fights myeloma

April 2007


Read Health24’s Comments Policy

Comment on this story
Comments have been closed for this article.

Ask the Expert

Cancer expert

CANSA’s purpose is to lead the fight against cancer in South Africa. Its mission is to be the preferred non-profit organisation that enables research, educates the public and provides support to all people affected by cancer. Questions are answered by CANSA’s Head of Health Professor Michael Herbst and Head of Advocacy Magdalene Seguin. For more information, visit

Still have a question?

Get free advice from our panel of experts

The information provided does not constitute a diagnosis of your condition. You should consult a medical practitioner or other appropriate health care professional for a physical exmanication, diagnosis and formal advice. Health24 and the expert accept no responsibility or liability for any damage or personal harm you may suffer resulting from making use of this content.

* You must accept our condition

Forum Rules